MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients - Brandes, A A; Franceschi, E; Tosoni, A (J Clin Oncol, 2008)
, et al.